Cardiovascular disease: Hormone replacement therapy and the window of opportunity

Cardiovascular Journal of South Africa

Volumn 16, Issue 4, 2005, Pages 229-230

  Cheifitz, R L ^a  

^a Christiaan Barnard Memorial Hospital   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTRADIOL; ESTROGEN; MATRIX METALLOPROTEINASE; PLACEBO; PROGESTERONE;

ARTERY DIAMETER; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CONFIDENCE INTERVAL; DEMENTIA; DISEASE MARKER; ENZYME BLOOD LEVEL; ESTROGEN THERAPY; GENE; HORMONE RESPONSIVE ELEMENT; HORMONE SUBSTITUTION; HUMAN; INTERNAL CAROTID ARTERY; ISCHEMIC HEART DISEASE; LETTER; LONG TERM CARE; LOW DRUG DOSE; MENOPAUSE; NONHUMAN; POSTMENOPAUSE; PRIMARY PREVENTION; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGE FACTORS; CARDIOVASCULAR DISEASES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MIDDLE AGED; TIME FACTORS;

EID: 28244500526     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (29)

1. Rapeport N. Editorial. Cardiovascular disease and hormone replacement therapy in post-menopausal women. Cardiovasc J South Afr 2005; 16(2): 76-80.
2. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens in heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. J Am Med Assoc 1995; 273: 199-208.
3. Smith DC, et al. Association of Exogenous Estrogen and Endometrial Carcinoma. N Eng J Med 1975; 293: 1164-1167.
4. Ziehl HK, et al. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Eng J Med 1975; 293: 1167-1170.
5. Hulley S, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary disease in postmenopausal women. J Am Med Assoc 1998; 280: 605-613.
6. Rossouw JE, et al. Risks and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Womens Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288: 321-333.
7. The Women's Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. J Am Med Assoc 2004; 291: 1701-1712.
8. Position statement by the executive committee of the International Menopause Society. Guidelines for the hormone treatment of women in the menopausal transition and beyond. Climacteric 2004; 7: 333-337.
9. Herrington DM, et al. Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Eng J Med 2000; 343: 522-529.
10. Manson JE, et al. Estrogen plus progestin and the risk of coronary heart disease. N Eng J Med 2003; 349: 523-534.
11. Grodstein F, et al. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-934.
12. Mendelsohn M, et al. The positive effects of estrogen on the cardiovascular system. N Eng J Med 1999; 340: 1801-1811.
13. Mosca L. The role of hormone replacement therapy in the prevention of postmenopausal heart disease. Arch Int Med 2000; 160: 2263-2272.
14. Adams MR, et al. Inhibitions of coronary atherosclerosis by 17 B-estradiol in ovariectomized monkeys: lack of an effect of added progesterone. Atherosclerosis 1990; 10: 1051-1057.
15. Lobo RA. Evaluation of cardiovascular events rates with hormone therapy in healthy, early menopausal women: results from two large clinical trials. Arch Intern Med 2004; 64: 482-484.
16. Hodis HN, et al. Hormone therapy and the progression of coronaryartery atherosclerosis in postmenopausal women. N Eng J Med 2003; 349: 535-529.
17. Hodis H, et al. Estrogen in the prevention of atherosclerosis trial. Circulation 2000; 102: 11-37.
18. Zangu D, et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. J Am Cell Cardiol 2000; 36: 1797-1802.
19. Harman S. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12.
20. Viscoli CM, et al. A clinical trial of estrogen replacement therapy after ischaemic stroke. N Eng J Med 2001; 345: 1243-1249.
21. Wasertheil-Smoller, et al. Effects of estrogen plus progestin on stroke in postmenopausal women. The Womens' Health Initiative: randomized trial. J Am Med Assoc 2003; 289: 2673-2684.
22. Shumaker S, et al. Conjugated equine estrogen plus progestin on the incidence of dementia and mild cognitive impairment in postmenopausal women: the Womens' health Initiative Memory Study. J Am Med Assoc 2003; 289: 2651-2662.
23. Shumaker S, et al. Conjugated equine estrogen plus progestin and incidence of probable demetial and mild cognitive impairment in postmenopausal women: Womens' Health Initiative Memory Study. J Am Med Assoc 2004; 291: 2947-2958.
24. Zandi PP, et al. Hormone replacement therapy and incidence of Alzheimer's disease in older women: the Cache County Study. J Am Med Assoc 2002; 88: 2123-2129.
25. Tang MX, et al. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996; 348: 429-432.
26. Kawas C, et al. A prospective study of estrogen replacement and the risk of developing Alzheimer's disease: the Balimore Longitudinal Study of Aging. Neurology 1997; 48: 1517-1521.
27. Cushman M, et al. Estrogen plus progestin and risk of venous thromboembolism. J Am Med Assoc 2004; 292: 1573-1580.
28. Position statement. Recommendations for estrogen and progestin use in peri and postmenopausal women: October 2004 Position statement of the North American Menopause Society. Menopause 2004; 6: 589-600.
29. Cheifitz R. Moratorium on hormone replacement therapy: Myth or reality? Specialist Forum 2005; 5: 4-10.